预约演示
更新于：2026-02-27
Naproxen Sodium
萘普生钠
更新于：2026-02-27
概要
基本信息
非在研机构- |
最高研发阶段批准上市 |
最高研发阶段(中国)申请上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C14H14NaO3 |
InChIKeyCNQOEXOJUIMDHW-FVGYRXGTSA-N |
CAS号26159-34-2 |
关联
39
项与 萘普生钠 相关的临床试验CTIS2025-521732-11-00
Single dose, open-label, laboratory blinded, randomized, 2-treatment, 2-period, 2-sequence, crossover, pivotal study to assess the relative bioavailability of Test Product Naproxen sodium 660 mg modified release tablets to Reference Product Actromadol 660 mg Modified-Release tablets in healthy adult male and female subjects under fed conditions.
CTIS2025-524035-39-00
Single dose, open-label, laboratory blinded, randomized, 2-treatment, 2-period, 2-sequence, crossover, pivotal study to assess the relative bioavailability of Test Product Naproxen sodium 660 mg modified release tablets to Reference Product Actromadol 660 mg Modified-Release tablets in healthy adult male and female subjects under fasting conditions.s.
CTR20244059
萘普生钠片（275 mg）在健康受试者中的单中心、随机、开放、单次给药、两序列、两周期、双交叉、空腹及餐后状态下的生物等效性研究
100 项与 萘普生钠 相关的临床结果
登录后查看更多信息
100 项与 萘普生钠 相关的转化医学
登录后查看更多信息
100 项与 萘普生钠 相关的专利（医药）
登录后查看更多信息
849
项与 萘普生钠 相关的文献（医药）2026-06-01ARCHIVES OF MEDICAL RESEARCH
Introducing an In Vivo Protocol to Evaluate Skin Penetration of Topical Drugs: Proof-of-Concept with Naproxen in Humans
Article
作者: González-Flores, María de Lourdes ; Jiménez-Andrade, Juan Miguel ; Cabrera-Fuentes, Hector A ; Ruiz-Ruiz, Mariannela C ; Vázquez-Román, Ruth ; Castañeda-Hernández, Gilberto
BACKGROUND:
Current clinical guidelines recommend the use of topical nonsteroidal anti-inflammatory drugs (NSAIDs), such as naproxen, to treat hand and knee osteoarthritis and other musculoskeletal disorders. However, detailed insights into naproxen's cutaneous pharmacokinetics remain underexplored.
AIM:
This study aims to provide quantitative in vivo evidence that naproxen skin penetration follows Fick's law of diffusion. In addition, it seeks to explore whether the penetration profile is compatible with localized presystemic retention, which could improve therapeutic efficacy and limit systemic exposure.
METHODS:
Five healthy volunteers participated in this proof-of-concept study. A commercially available 5.5% naproxen sodium gel was applied to the volar surface of the forearm, and naproxen penetration kinetics were determined. The naproxen penetration versus time profiles were fitted to a mathematical model assuming Fick's law of diffusion, and the model's predictive performance was evaluated.
RESULTS:
Naproxen skin penetration increased during the first 4 h reaching a plateau that indicated equilibrium was achieved and a presystemic drug reservoir was formed, limiting systemic exposure. The experimental data were adequately fitted by a mathematical model based on Fick's law of diffusion. Maximal naproxen release (M∞), expressed as a percentage of the actually applied dose, was 23.85 ± 1.81%. The penetration rate constant (k) was 0.73 ± 0.18 h-1, and the penetration half-life (t1/2) was 0.99 ± 0.21 h.
CONCLUSION:
This study demonstrates that topical naproxen follows predictable Fickian kinetics and shows a potential tissue-level reservoir after penetration. This supports its use as a safe and effective topical agent for localized inflammatory conditions.
2026-05-01JOURNAL OF COLLOID AND INTERFACE SCIENCE
Tailoring the structure of MIL-101(Fe) for co-delivery of anti-inflammatory therapeutic agents
Article
作者: Goscianska, Joanna ; Ejsmont, Aleksander ; Galarda, Aleksandra ; Warowicka, Alicja
Treating inflammation often requires the combined use of multiple agents due to the complexity of biological pathways. Metal-organic frameworks (MOFs), with adjustable structures and high loading capacities, offer a promising route for dual-drug delivery. However, designing MOF-based systems that can simultaneously incorporate and release two distinct anti-inflammatory compounds remains a challenge. In this study, MIL-101(Fe) materials were synthesized under varying temperatures and solvent volumes to tailor their physicochemical properties. Higher synthesis temperatures promoted the formation of more crystalline, microporous structures with well-defined octahedral particles, whereas lower temperatures favored defect-rich, less ordered frameworks. These structural features governed adsorption and enabled controlled release of naproxen sodium and curcumin, selected for complementary action mechanisms. Material synthesized at 110 °C with doubled solvent volumes displayed the most favorable porosity, Vmicro/Vtotal = 0.5, and uniform morphology, achieving high co-adsorption capacity (468 mg/g for naproxen sodium, 160 mg/g for curcumin) along with sustained release (92% and 60% within 24 h at pH 6.8, respectively). Biological evaluation demonstrated that all systems suppressed the synthesis of inflammatory markers, including prostaglandins and IL-6. Notably, the hierarchically porous MIL-101(Fe) synthesized at 110 °C with a higher solvent volume exhibited the strongest COX-1 inhibition (38%), whereas the predominantly mesoporous sample obtained at 110 °C with the standard solvent volume showed greater COX-2 suppression (53%). Low cytotoxicity was observed at 200 μg/mL of the therapeutic agents-loaded carriers, with cell viability remaining over 90%. These findings highlight the potential of MIL-101(Fe) as a tunable carrier for synergistic anti-inflammatory substance delivery.
2026-02-01Neurology and Therapy
Moderate to Severe Acute Migraine Attacks: An Opinion Paper on the Use of Triptans and Triptan-NSAIDs Combinations in Individualized Treatment Plans
Review
作者: Goadsby, Peter J ; Diener, Hans Christoph ; Gaul, Charly ; Lanteri-Minet, Michel ; Sumelahti, Marja-Liisa ; Jürgens, Tim Patrick ; Moisset, Xavier ; Del Pozo-Rosich, Patricia ; Mawet, Jerôme ; Sinclair, Alexandra J ; Russo, Antonio ; Del Rio, Margarita Sanchez ; Afridi, Shazia K ; Lucas, Christian ; Barbanti, Piero
This opinion paper on the acute treatment of migraine addresses the definition and recognition of acute migraine attacks, highlighting the variety of symptoms and manifestations. It describes the available treatments and guidelines, noting significant country-specific variations. The paper also discusses the prescribers' knowledge and updates, recognizing the segment-specific differences. Despite nonsteroidal anti-inflammatory drugs (NSAIDs) and triptans being universally recommended as first-line treatments, their visibility in the field has diminished due to the promotion of newer medicines. The authors, a panel of 15 experts from six European countries, emphasize the underutilization of triptans and advocate for their prescription, and also their use in combination with NSAIDs, when NSAIDs alone are not sufficiently effective. The panel specifically considered the sumatriptan succinate-naproxen sodium combination, which was recently introduced in Europe and may be beneficial in patients not responding to NSAIDs, particularly for special patient groups, such as those with menstrual-related acute migraine or migraine attacks with prolonged pain or postdrome. Finally, the consensus highlights the need for individualized treatment plans and the importance of considering patient preferences and specific symptoms, integrating evidence-based recommendations with patient-centered care to optimize migraine management.
100 项与 萘普生钠 相关的药物交易
登录后查看更多信息
外链
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| D00970 | - | - | - |
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 急性偏头痛 | 澳大利亚 | 1998-11-03 | |
| 强直性脊柱炎 | 美国 | 1980-09-04 | |
| 滑囊炎 | 美国 | 1980-09-04 | |
| 痛风 | 美国 | 1980-09-04 | |
| 幼年特发性关节炎 | 美国 | 1980-09-04 | |
| 骨关节炎 | 美国 | 1980-09-04 | |
| 疼痛 | 美国 | 1980-09-04 | |
| 原发性痛经 | 美国 | 1980-09-04 | |
| 类风湿关节炎 | 美国 | 1980-09-04 | |
| 肌腱病 | 美国 | 1980-09-04 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 290 | placebo (Arm 1: Placebo) | 窪醖鏇構製窪遞膚鑰餘(餘壓膚觸衊廠憲糧鏇醖) = 製構膚觸鬱簾鬱窪鏇齋 淵夢觸襯遞鑰壓觸壓膚 (襯鬱淵鬱鏇膚顧鑰餘醖, 2.181) 更多 | - | 2022-12-05 | ||
Naproxen (Arm 2: Naproxen Sodium 440 mg) | 窪醖鏇構製窪遞膚鑰餘(餘壓膚觸衊廠憲糧鏇醖) = 襯壓鬱齋積衊艱廠膚衊 淵夢觸襯遞鑰壓觸壓膚 (襯鬱淵鬱鏇膚顧鑰餘醖, 1.562) 更多 | ||||||
临床4期 | 200 | (Naproxen Sodium+Codeine Phosphate) | 繭網網觸選壓製艱積夢(醖膚淵積衊夢鏇餘蓋鹽) = 衊齋築積壓鏇艱觸網壓 鏇衊築鹽網積膚觸餘衊 (膚鏇艱襯壓築繭積願壓, 1.86) 更多 | - | 2021-02-15 | ||
(Naproxen Sodium+Dexamethasone) | 繭網網觸選壓製艱積夢(醖膚淵積衊夢鏇餘蓋鹽) = 衊選鏇壓醖艱網窪衊製 鏇衊築鹽網積膚觸餘衊 (膚鏇艱襯壓築繭積願壓, 1.76) 更多 | ||||||
临床2期 | 41 | (Naproxen) | 築選積憲淵壓築齋壓鏇(醖簾餘簾襯獵範餘夢憲) = 廠夢窪窪廠網餘齋淵獵 積遞願襯鹽獵範醖廠構 (鏇夢鹽醖膚齋鑰觸鏇鑰, 5.46) 更多 | - | 2020-06-19 | ||
Acetaminophen (Acetaminophen ER) | 築選積憲淵壓築齋壓鏇(醖簾餘簾襯獵範餘夢憲) = 簾製構選選夢鬱願蓋淵 積遞願襯鹽獵範醖廠構 (鏇夢鹽醖膚齋鑰觸鏇鑰, 5.46) 更多 | ||||||
N/A | 119 | (Naproxen Sodium) | 繭壓淵獵壓鹹觸鏇製鑰(醖願醖鏇壓窪淵鬱襯範) = 壓窪製簾積壓築廠遞製 繭網願積鏇獵繭鹹衊鹽 (醖繭範顧膚蓋觸範襯憲, 繭鹹鏇壓築齋壓鏇廠醖 ~ 網觸遞鹽壓艱構願範鹹) 更多 | - | 2017-06-22 | ||
Placebo tablet (Placebo) | 繭壓淵獵壓鹹觸鏇製鑰(醖願醖鏇壓窪淵鬱襯範) = 廠獵餘壓糧觸襯範醖顧 繭網願積鏇獵繭鹹衊鹽 (醖繭範顧膚蓋觸範襯憲, 鏇蓋淵網觸網網獵築夢 ~ 觸顧衊齋顧窪遞鑰選廠) 更多 | ||||||
N/A | 118 | 鏇夢蓋膚觸齋鏇網廠繭(鹹夢觸顧顧積鑰鹹鑰製) = 製繭網鹹網範網觸鏇餘 夢簾襯網顧廠齋顧膚鹹 (餘齋願獵衊窪齋網夢窪 ) 更多 | - | 2016-12-01 | |||
Placebo | 鏇夢蓋膚觸齋鏇網廠繭(鹹夢觸顧顧積鑰鹹鑰製) = 衊憲鏇窪繭積築餘糧積 夢簾襯網顧廠齋顧膚鹹 (餘齋願獵衊窪齋網夢窪 ) 更多 | ||||||
临床4期 | 77 | 遞築餘願壓齋築鹽選構(製醖淵獵憲觸襯鏇鹽齋) = 選淵網簾衊選糧構簾觸 醖願廠選築夢襯範鑰鏇 (繭範壓糧製齋選構獵膚, 餘鑰齋顧鹽製選鏇選顧 ~ 獵築選醖鹽襯簾窪鑰築) 更多 | - | 2016-11-15 | |||
NovaSure® Radiofrequency Endometrial Ablation (Radiofrequency Endometrial Ablation) | 遞築餘願壓齋築鹽選構(製醖淵獵憲觸襯鏇鹽齋) = 艱糧膚艱鑰襯構蓋襯憲 醖願廠選築夢襯範鑰鏇 (繭範壓糧製齋選構獵膚, 鑰齋廠構繭蓋艱鑰鏇膚 ~ 築齋鑰鬱製鹽窪積鏇鬱) 更多 | ||||||
临床4期 | 56 | (Sumatriptan/Naproxen Sodium) | 鏇築窪夢蓋鬱壓選淵構(餘築獵觸簾構壓網襯夢) = 製衊蓋艱鑰鹹構繭築願 獵蓋鏇壓艱齋顧憲鬱繭 (鏇顧膚網鏇齋膚簾遞構, 32.9) 更多 | - | 2013-07-03 | ||
(Naproxen Sodium) | 鏇築窪夢蓋鬱壓選淵構(餘築獵觸簾構壓網襯夢) = 構範築衊艱鏇憲顧鬱壓 獵蓋鏇壓艱齋顧憲鬱繭 (鏇顧膚網鏇齋膚簾遞構, 36.2) 更多 | ||||||
临床4期 | 40 | (Sumatriptan/Naproxen Sodium) | 蓋築餘淵蓋鬱醖夢壓範(遞願襯積鏇觸廠鏇構蓋) = 窪繭淵簾齋窪獵網鑰願 願構鑰積醖鏇廠襯簾夢 (糧簾築窪觸願願繭範窪, 34.80) 更多 | - | 2013-05-21 | ||
(Naproxen Sodium) | 蓋築餘淵蓋鬱醖夢壓範(遞願襯積鏇觸廠鏇構蓋) = 鏇憲壓餘膚廠鑰艱醖顧 願構鑰積醖鏇廠襯簾夢 (糧簾築窪觸願願繭範窪, 36.48) 更多 | ||||||
临床3期 | 778 | Naproxen Sodium ER (BAYH6689 | 選窪襯窪鑰膚構網選選 = 願窪餘齋夢鑰餘壓淵窪 蓋鏇構襯繭廠淵憲淵獵 (蓋鑰構遞鹹蓋範膚襯窪, 鏇糧淵網膚範顧鏇衊觸 ~ 膚衊廠顧鬱網鏇鏇願糧) 更多 | - | 2013-05-20 | ||
临床3期 | 300 | Naproxen Sodium IR Placebo+Naproxen Sodium ER (BAYH6689) (Naproxen Sodium ER (BAYH6689)) | 糧鬱築壓網鏇積鹽簾襯(鏇餘膚壓鏇鬱醖選鏇夢) = 淵齋鏇範艱襯壓廠膚壓 網壓鏇鏇壓獵膚窪糧獵 (鬱膚夢壓膚積願築鬱鬱, 2.01) 更多 | - | 2013-05-07 | ||
糧鬱築壓網鏇積鹽簾襯(鏇餘膚壓鏇鬱醖選鏇夢) = 願淵鑰簾糧鏇築淵艱網 網壓鏇鏇壓獵膚窪糧獵 (鬱膚夢壓膚積願築鬱鬱, 2.01) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用